NewsRoom Articles

ThursdayMar 26, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials These developments position the company at the intersection of innovation and therapeutics Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side…

WednesdayMar 25, 2026 10:00 am

Political Campaigns Start Featuring Ads Created Using AI

Artificial intelligence has moved from a background tool into a visible presence in American political advertising and its arrival is generating real friction well ahead of the 2026 midterm cycle. Campaign teams at every level of electoral competition are finding ways to work it into their advertising, but unfortunately, it's not always in ways that voters would recognize as synthetic. The case drawing the most attention comes from Massachusetts. A Republican primary campaign produced a radio spot featuring a machine-generated voice crafted to sound like Democratic Governor Maura Healey, articulating positions she has no record of taking. Both videos portrayed…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

MondayMar 23, 2026 10:00 am

Fewer Men Undergo Cancer Screening, Study Shows

Men make up just 5% of people getting genetic tests for inherited cancer risks despite dying from cancer at higher rates than women, new research shows. Analysis of more than 224,000 tests revealed men who do get screened face much higher odds of carrying dangerous genetic mutations, with positive results hitting 14% versus 8% for women. The gap represents a major blind spot in cancer prevention. Genetic screening spots inherited vulnerabilities to breast, ovarian, prostate, and colon cancers, letting doctors track high-risk patients and step in early. Women benefit from widespread protocols urging doctors to evaluate hereditary breast and ovarian cancer factors during routine care. Similar systems cover other…

FridayMar 20, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is…

WednesdayMar 18, 2026 10:00 am

Scientists Discover Why Colon Cancer Diagnoses are Increasing in Young Adults

Researchers have found that people under 50 who develop colorectal cancer have unusually rigid colon tissue that helps tumors grow, offering the first clear explanation for rising cancer rates in younger adults. A University of Texas at Dallas team working with UT Southwestern Medical Center discovered that both tumor samples and surrounding healthy tissue were mechanically stiffer in younger patients than in older people with the same disease. Physical tissue properties appear to drive early-onset colorectal cancer, which has become the top cancer killer among Americans under 50. UT Dallas bioengineering Assistant Professor Jacopo Ferruzzi says this marks the first study showing how mechanical forces contribute to…

MondayMar 16, 2026 10:00 am

US Military Admits it is Using AI in Attacks Against Iran

The U.S. military has confirmed that AI systems are actively involved in its ongoing operations against Iran, an admission that has added significant fuel to an international debate that was already running hot. Brad Cooper, commander of U.S. Central Command, outlined the role of artificial intelligence systems in a publicly released video. He positioned AI as critical infrastructure for processing the enormous volumes of information that flow through a modern military campaign. Cooper was explicit that the technology shapes the conditions in which decisions are made. It compresses analysis that once took many hours into something commanders can act on almost immediately. He also said that human judgment is…

MondayMar 16, 2026 9:45 am

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options. Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer. LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined,…

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

WednesdayMar 11, 2026 10:00 am

Researchers Trace Differing Pediatric Brain Tumors to Common Source

New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find. Pineoblastoma originates in the pineal gland, a small structure at the brain's core responsible for producing hormones, including melatonin. Cases are rare enough that most specialized pediatric oncology programs handle only a small number each year. Pooling resources across three institutions, St. Jude Children's Research…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000